5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines

1. A compound of formula (I)

wherein

R 1 is a group selected from:

wherein * indicates the point of attachment of said group with the rest of the molecule;

R 2 is hydrogen, —NR 7 R 8 , CN, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, 3- to 10-membered heterocycloalkoxy, C 2 -C 6 -alkenyl, C 3 -C 6 -cycloalkyl, C 4 -C 6 -cycloalkenyl, 3- to 10-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, phenyl, heteroaryl, —(CO)OR 7 , —(CO)NR 7 R 8 , —(SO 2 )R 9 , —(SO)R 9 , —SR 9 , —(SO 2 )NR 7 R 8 , —NR 7 (SO 2 )R 9 , —((SO)═NR 11 )R 10 , —N═(SO)R 9 R 10 , —SiR 10 R 11 R 12 , —(PO)(OR 7 ) 2 , —(PO)(OR 7 )R 10 or —(PO)(R 10 ) 2 ,

wherein each C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, 3- to 10-membered heterocycloalkoxy, C 2 -C 6 -alkenyl, C 3 -C 6 -cycloalkyl, 3- to 10-membered heterocycloalkyl, phenyl or heteroaryl is optionally substituted, one or more times, independently from each other, with halogen, OH, —CN, —NR 7 R 8 , C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, C 1 -C 4 -hydroxyalkyl, phenyl-C 1 -C 4 -alkyl, (C 1 -C 4 -alkoxy)-(C 1 -C 4 -alkyl)-, C 1 -C 6 -alkoxy, C 3 -C 6 -cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, —(CO)OR 7 , —(CO)NR 7 R 8 , —NR 7 (CO)R 10 , —NR 8 (CO)OR 7 , —NR 8 (CO) NR 7 R 8 , —(SO 2 )R 9 , —(SO)R 9 , —SR 9 , —(SO 2 )NR 7 R 8 , —NR 7 (SO 2 )R 9 , —((SO)═NR 11 )R 10 , —N═(SO)R 9 R 10 , —(PO)(OR 7 ) 2 , —(PO)(OR 7 )R 10 , —(PO)(R 10 ) 2 , with a heteroaryl group which is optionally substituted one or more times with C 1 -C 4 -alkyl, or

wherein two substituents of said phenyl group attached to two adjacent phenyl ring atoms are linked to one another to jointly form a methylenedioxy, ethylenedioxy, ethyleneoxy or trimethyleneoxy group;

wherein each 4- to 10-membered heterocycloalkenyl is optionally substituted, one or more times, independently from each other, with C 1 -C 4 -alkyl;

R 3 and R 4 are independently hydrogen or methyl;

R 5 is C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl or C 1 -C 6 -alkoxy;

R 7 and R 8 are independently hydrogen, C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, phenyl or phenyl-CH 2 —, which phenyl is optionally substituted, one or more times, with halogen; or

R 7 and R 8 together represent a 4-, 5-, 6- or 7-membered cyclic amine group, which is optionally substituted, one or more times, independently from each other, with a substituent selected from C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, said 4-, 5-, 6- or 7-membered cyclic amine group optionally containing one further heteroatom selected from the group consisting of O, N and S;

R 9 is C 1 -C 4 -alkyl or phenyl, wherein each C 1 -C 4 -alkyl or phenyl is optionally substituted, one or more times, independently from each other, with R 13 ;

R 10 is C 1 -C 4 -alkyl; or

R 9 and R 10 together, in case of —N═(SO)R 9 R 10 group, represent a 5- to 8-membered heterocycloalkyl group;

R 11 is hydrogen, C 1 -C 4 -alkyl, —(CO)OR 7 , —(CO)NR 7 R 8 or CN;

R 12 is hydrogen or C 1 -C 4 -alkyl; and

R 13 is halogen, OH, —NR 7 R 8 , CN, NO 2 , C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkoxy, C 2 -C 6 -alkenyl, C 3 -C 6 -cycloalkyl, —(CO)OR 7 or —(CO)NR 7 R 8 ,

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

2. The compound of formula (I) according to claim 1 , wherein:

R 1 is a group:

wherein * indicates the point of attachment of said group with the rest of the molecule;

R 2 is hydrogen, —NR 7 R 8 , CN, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, 3- to 6-membered heterocycloalkoxy, C 3 -C 6 -cycloalkyl, C 4 -C 6 -cycloalkenyl, 3- to 6-membered heterocycloalkyl, phenyl, heteroaryl, —(CO)OR 7 , —(CO)NR 7 R 8 , —(SO 2 )R 9 , —(SO)R 9 , —SR 9 , —(SO 2 )NR 7 R 8 , —NR 7 (SO 2 )R 9 , —((SO)═NR 11 )R 10 , —N═(SO)R 9 R 10 , —(PO)(OR 7 ) 2 , —(PO)(OR 7 )R 10 or —(PO)(R 10 ) 2 ,

wherein each C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, 3- to 6-membered heterocycloalkoxy, C 3 -C 6 -cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl or heteroaryl is optionally substituted, one or more times, independently from each other, with halogen, OH, —CN, —NR 7 R 8 , C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 1 -C 4 -hydroxyalkyl, phenyl-C 1 -C 2 -alkyl, (C 1 -C 4 -alkoxy)-(C 1 -C 4 -alkyl)-, C 1 -C 4 -alkoxy, C 3 -C 6 -cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, —(CO)OR 7 , —(CO)NR 7 R 8 , —NR 7 (CO)R 10 , —NR 8 (CO)OR 7 , —NR 8 (CO) NR 7 R 8 , —(SO 2 )R 9 , —(SO)R 9 , —SR 9 , —(SO 2 )NR 7 R 8 , —NR 7 (SO 2 )R 9 , —((SO)═NR 11 )R 10 , —N═(SO)R 9 R 10 , with a heteroaryl group which is optionally substituted one or more times with C 1 -C 4 -alkyl, or

wherein two substituents of said phenyl group attached to two adjacent phenyl ring atoms are linked to one another to jointly form a methylenedioxy, ethylenedioxy, ethyleneoxy or trimethyleneoxy group;

R 3 and R 4 are independently hydrogen or methyl;

R 5 is C 1 -C 4 -alkyl;

R 7 and R 8 are independently hydrogen, C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, phenyl or phenyl-CH 2 —, which phenyl is optionally substituted, one or more times, with halogen; or

R 7 and R 8 together represent a 5- or 6-membered cyclic amine group, which is optionally substituted, one or more times, independently from each other, with a substituent selected from C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, said 5- or 6-membered cyclic amine group optionally containing one further heteroatom selected from the group consisting of O, N and S;

R 9 is C 1 -C 4 -alkyl;

R 10 is C 1 -C 4 -alkyl; or

R 9 and R 10 together, in case of —N═(SO)R 9 R 10 group, represent a 5- to 6-membered heterocycloalkyl group; and

R 11 is hydrogen or C 1 -C 4 -alkyl,

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

3. The compound according to claim 1 , wherein the compound of formula (I) is a compound of formula (Ib)

wherein:

R 1 is a group:

wherein * indicates the point of attachment of said group with the rest of the molecule;

R 2 is NR 7 R 8 , C 1 -C 4 -alkoxy, C 4 -C 6 -cycloalkenyl, 6-membered heterocycloalkyl, phenyl, heteroaryl, —(CO)OR 7 , —N═(SO)R 9 R 10 , —(PO)(OR 7 )R 10 or —(PO)(R 10 ) 2 ,

wherein each C 1 -C 4 -alkoxy, 6-membered heterocycloalkyl, phenyl or heteroaryl is optionally substituted, one or more times, independently from each other, with halogen, OH, —CN, —NR 7 R 8 , C 1 -C 4 -alkyl, hydroxymethyl, phenyl-CH 2 —, methoxymethyl, C 1 -C 4 -alkoxy, 6-membered heterocycloalkyl, —(CO)OR 7 , —(CO)NR 7 R 8 , —(SO 2 )R 9 , —(SO)R 9 , —SR 9 , —NR 7 (SO 2 )R 9 , or

wherein two substituents of said phenyl group attached to two adjacent phenyl ring atoms are linked to one another to jointly form an ethylenedioxy group;

R 4 is methyl;

R 5 is methyl;

R 7 and R 8 are independently hydrogen, C 1 -C 6 -alkyl, cyclopropyl, phenyl or phenyl-CH 2 —, which phenyl is optionally substituted, one or more times, with halogen; or

R 7 and R 8 together represent a 5-membered cyclic amine group;

R 9 is methyl or ethyl; and

R 10 is methyl or ethyl; or

R 9 and R 10 together, in case of —N═(SO)R 9 R 10 group, represent a 5-membered heterocycloalkyl group;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

4. The compound according to claim 1 , wherein the compound of formula (I) is a compound of formula (Ib),

wherein:

R 1 is a group:

wherein * indicates the point of attachment of said group with the rest of the molecule;

R 2 is N-methyl-(2,2-dimethylpropyl), propan-2-yloxy, cyclopent-1-en-1-yl, 6-membered heterocycloalkyl, phenyl, heteroaryl, —(CO)O-methyl, —N═(SO)diethyl, —N═(SO)(CH 2 ) 4 , —(PO)(O-ethyl)methyl, —(PO)(O-(2-methylpropyl))methyl or (PO)(methyl) 2 ,

wherein each 6-membered heterocycloalkyl, phenyl or heteroaryl is optionally substituted, one or more times, independently from each other, with halogen, OH, —CN, —NR 7 R 8 , C 1 -C 4 -alkyl, hydroxymethyl, phenyl-CH 2 —, methoxymethyl, C 1 -C 4 -alkoxy, 6-membered heterocycloalkyl, —(CO)OR 7 , —(CO)NR 7 R 8 , —(SO 2 )R 9 , —(SO)R 9 , —SR 9 , —NR 7 (SO 2 )R 9 , or

wherein two substituents of said phenyl group attached to two adjacent phenyl ring atoms are linked to one another to jointly form an ethylenedioxy group;

R 4 is methyl;

R 5 is methyl;

R 7 and R 8 are independently hydrogen, C 1 -C 5 -alkyl, cyclopropyl, phenyl or unsubstituted phenyl-CH 2 —, which phenyl is optionally substituted, one or more times, with halogen; or

R 7 and R 8 together represent a 5-membered cyclic amine group;

R 9 is methyl or ethyl; and

R 10 is methyl or ethyl; or

R 9 and R 10 together, in case of —N═(SO)R 9 R 10 group, represent a tetramethylene group;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

5. The compound according to claim 1 , wherein the compound of formula (I) is a compound of formula (Ib),

wherein:

R 1 is a group:

wherein * indicates the point of attachment of said group with the rest of the molecule;

R 2 is propan-2-yloxy, —N═(SO)diethyl, —(PO)(O-ethyl)methyl, 1-methyl-1H-pyrazol-5-yl, morpholin-4-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-(methyl sulfonyl)piperazin-1-yl, 1-methyl-1H-imidazol-5-yl or 2-methyl-1,3-thiazol-5-yl;

R 4 is methyl; and

R 5 is methyl,

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

6. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-4-(propan-2-yloxy)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

4-(2-fluoropyridin-3-yl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

5-methyl-4-[2-methyl-6-(methyl sulfonyl)pyridin-3-yl]-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

4-(2-chloro-1-methyl-1H-imidazol-5-yl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

4-[2-fluoro-4-(piperazin-1-yl)phenyl]-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

4-(2,3-difluorophenyl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

N-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yltetrahydro-1H-1 λ 4 -thiophen-1-imine 1-oxide;

4-[diethyl(oxido)-λ 6 -sulfanylidene]amino-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-4-(morpholin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

(1-{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}piperidin-4-yl)methanol;

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-4-[4-(methyl sulfonyl)piperazin-1-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

N-(2,2-dimethylpropyl)-N, 5-dimethyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-amine;

methyl 5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine-4-carboxylate;

5-methyl-4-(1-methyl-1H-imidazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-4-(2-methyl-1,3-thiazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

ethyl methyl{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}phosphinate;

4-(dimethylphosphoryl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

2-methylpropyl methyl{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}phosphinate;

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-4-phenyl-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

4-(2,4-dichlorophenyl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

(3-{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}phenyl)methanol;

4-(4-fluorophenyl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

4-(4-methoxyphenyl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-4-(2,3,5-trifluorophenyl)-1,7-naphthyridine;

4-(6-methoxypyridin-3-yl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

methyl 3-{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}benzoate;

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-4-[4-(methylsulfinyl)phenyl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

4-(2-fluoro-3-methoxyphenyl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-4-[2-(methylsulfonyl)phenyl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

N-(4-{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}phenyl)methanesulfonamide;

4-(cyclopent-1-en-1-yl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-4-(quinolin-3-yl)-1,7-naphthyridine;

N,N-dimethyl-4-{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}benzamide;

4-(4-chloro-3-methylphenyl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

4-(2,3-dimethoxyphenyl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

4-(4-chloro-2-methoxyphenyl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-4-[4-(methylsulfanyl)phenyl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

N,N-dimethyl-3-{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}aniline;

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-4-[3-(methylsulfonyl)phenyl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

4-(3,5-dimethoxyphenyl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-4-(quinolin-4-yl)-1,7-naphthyridine;

4-(1H-indol-4-yl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

4-(1H-indol-6-yl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-4-(3-methylpyridin-4-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

(5-{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}thiophen-2-yl)methanol;

2-fluoro-4-{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}benzonitrile;

4-(6-fluoropyridin-3-yl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

4-(2-methoxypyridin-3-yl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-4-[2-(propan-2-yl)phenyl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

4-{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}benzamide;

(4-{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}phenyl)(pyrrolidin-1-yl)methanone;

N-benzyl-4-{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}benzamide;

N,N-dimethyl-3-{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}benzamide;

4-[3-(methoxymethyl)phenyl]-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

5-methyl-4-(1-methyl-1H-indol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

4-(isoquinolin-4-yl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

4-(5-methoxypyridin-3-yl)-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-4-[3-(propan-2-yloxy)phenyl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-4-(4-methylpyridin-3-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine;

N-tert-butyl-4-{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}benzamide;

N-cyclopropyl-4-{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}benzamide;

3-methyl-4-{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}phenol;

4-[4-(methoxymethyl)phenyl]-5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine; and

N-methyl-4-{5-methyl-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-4-yl}benzamide;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

7. A method for treatment of cervical cancer in a human or animal in need thereof, comprising administering an effective amount of a compound of formula (I) according to claim 1 to the human or animal.

8. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 and one or more pharmaceutically acceptable excipient(s).

9. A method for treatment of cervical cancer in a human or animal in need thereof, comprising administering an effective amount of a pharmaceutical composition according to claim 8 to the human or animal.

10. A pharmaceutical combination comprising:

one or more active ingredient(s) selected from a compound of formula (I) according to claim 1 , and

one or more active ingredient(s) selected from antihyperproliferative, cytostatic or cytotoxic substances for treatment of cancers.

11. A pharmaceutical composition comprising a compound of formula (Ib) according to claim 3 and one or more pharmaceutically acceptable excipient(s).

12. A pharmaceutical combination comprising:

one or more active ingredient(s) selected from a compound of formula (Ib) according to claim 3 , and

one or more active ingredient(s) selected from antihyperproliferative, cytostatic or cytotoxic substances for treatment of cancers.

13. A method for treatment of cervical cancer in a human or animal in need thereof, comprising administering an effective amount of a compound of formula (Ib) according to claim 3 to the human or animal.

14. A method for treatment of cervical cancer in a human or animal in need thereof, comprising administering an effective amount of a pharmaceutical combination according to claim 12 to the human or animal.